CDKN2A and pancreatic neoplasm: On the other hand, other studies have shown that either p16 or p53 loss, in conjunction with constitutive KRAS, promoted pancreatic cancer progression, thus indicating that both the retinoblastoma and the p53 pathway are involved in the suppression of pancreatic cancer development [79].